Obey Martin Manayiti

KKR identifies industrial automation, worker reskilling, AI, decarbonization as mega themes; Vista still likes enterprise software

KKR releases its 2024 global macro outlook.

Vista's Patrick Severson: Promising enterprise software sectors in 2024 include cybersecurity, energy transition, healthcare IT

Vista signed two platform investments, TRG Screen and Energy Exemplar, in H2 despite the deal downturn.

Inside the exit: How Vestar grew foodservice biz during covid lockdowns and sold it to Sysco

Edward Don & Co made four acquisitions under Vestar: Myers Restaurant Supply, Shervan Colonel Equipment, Atlanta Fixture & Sales Co and Smith & Greene.

Inside the exit: Gryphon Investors' Mark Fuller on fire and safety opportunities

Gryphon invested in Potter Global Technologies in 2017 before exiting to KKR in November.

Rite Aid auctions postponed; LFM finds opportunities in US-based manufacturing of circuit boards

'A lot of printed circuit board assembly had moved offshore but we have seen, probably over the last six or seven years, a trend towards moving manufacturing back to the US,' said LFM Capital’s Steve Cook.

LFM bets on SisTech circuit boards as manufacturing moves back to the US

SisTech is the sixth platform company in LFM’s third fund of $310m, which closed in 2022.

Inside the exit: Riverside invested in tech and talent to grow Energy Exemplar

Riverside is selling the Australian business, which develops simulation software for power companies, to Blackstone and Vista.

MSCP-backed Alliance Technical Group closes four more add-ons; plus 10 PE-backed CRO deals

Private equity goes bullish over clinical trials.

MSCP finds opportunities with environmental labs, scoops up four add-ons to Alliance Technical Group

The four add-ons are Summit Environmental Technologies, Fremont Analytical, Orange Coast Analytical and Chester LabNet.

Drug development: 10 PE-backed deals show interest in clinical trials

NMS Capital, QHP Capital, VSS Capital, and FFL Partners are some of the firms persuing opportunities in clinical trials.